LONG-TERM RESPONSE TO CRIZOTINIB IN A 17-YEAR-OLD BOY WITH NAÏVE
ALK-POSITIVE NON-SMALL-CELL LUNG CANCER
Megaro Giacomina1*, Miele Evelina1,
Spinelli Gian Paolo2, Alessi Iside1,
Del Baldo Giada1, Cozza Raffaele1,
Russo Ida1, De Pasquale Maria
Debora1, Cefalo Maria Giuseppina1,
Tomà Paolo3, Di Ruscio Valentina1,
De Ioris, Maria Antonietta1, Mastronuzzi
Angela1
1 Department of Hematology/Oncology, Cell and Gene
Therapy, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy
2 UOC Oncologia Universitaria, ASL Latina (distretto
Aprilia), Sapienza University of Rome- Aprilia, Latina, Italy.
3 Department of Imaging, Bambino Gesù Children’s Hospital, IRCCS, Rome,
Italy.
* Corresponding author: Giacomina Megaro, Piazza di Sant’Onofrio
4, Rome, 00165, Italy,giacomina.megaro@opbg.net; Tel.: 00393884699597;
Abstract: 99 words
Main text: 1127 words
Tables: 1
Figures: 1
Keywords: lung, adenocarcinoma, ALK, adolescence, crizotinib